

Supplement Table S3. Psoriasis Area and Severity Index score at week 12, 24, 36 and 48 during secukinumab treatment.

	Psoriasis Area and Severity Index score			
	Without prior bio-failure	With prior bio-failure		Total
	Mean/Median (IQR)	Mean/Median (IQR)	P-value	Mean/Median (IQR)
Week 0	15.8/ 14.4 (10.5)	20.7 / 18.6 (12.8)	0.007**	18.5 / 15.8 (12.4)
Week 4	5.4 / 4.5 (5.3)	7.3 / 6.1 (8.0)	0.076	6.4 / 5.1 (6.9)
week 12	2.8 / 2.5 (3.1)	5.0 / 4.1 (5.4)	0.009**	4.0 /2.7 (4.5)
Week 24	2.8 / 2.2 (3.2)	4.8/ 3.8 (4.6)	0.011*	3.9 / 2.5 (4.3)
Week 36	2.6 /1.6 (3.0)	5.7 /3.9 (5.5)	0.007**	4.7 / 3.1 (5.3)
Week 48	3.4 /2.7 (4.4)	6.7 / 5.2 (5.9)	0.027*	5.6 / 4.3 (6.2)

IQR, interquartile range; * p <0.05, ** p <0.01, *** p<0.001 for comparison between patients with and without prior biologic failure.